Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Cluster Analysis Followed by Network Meta-Analysis to Compare Efficacy and Safety of Dabigatran, Rivaroxaban and Apixaban After Elective Total Knee and Hip Replacement Surgery

Job Harenberg, Prof., Dr., Svetlana Marx, Shabnam Zolfaghari, Christel Weiss, Dr., Martin Wehling, Prof., Dr., Astrid Schulze, Dr., Ola E Dahl, MD

Blood (2012) 120 (21): 3409.

https://doi.org/10.1182/blood.V120.21.3409.3409

Published: 2012

Journal Articles

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Joachim Stangier, PhD, Bengt I Eriksson, MD, Michael H Huo, MD, Richard J Friedman, MD, Ola E Dahl, MD, Martin Feuring, MD

Blood (2011) 118 (21): 2307.

https://doi.org/10.1182/blood.V118.21.2307.2307

Published: 2011

Journal Articles

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Michael H Huo, MD, Andreas A Kurth, MD, Ola E Dahl, MD, Andreas Clemens, MD, Stefan Hantel, PhD, Martin Feuring, MD, Richard J Friedman, MD, Bengt I Eriksson, MD, PhD

Blood (2011) 118 (21): 2312.

https://doi.org/10.1182/blood.V118.21.2312.2312

Published: 2011

Journal Articles

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

Ajay K. Kakkar, MD, PhD, Benjamin Brenner, MD, Ola E. Dahl, MD, PhD, Bengt I. Eriksson, MD, PhD, Patrick Mouret, MD, Jim Muntz, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD, Sylvia Haas, MD

Blood (2007) 110 (11): 307.

https://doi.org/10.1182/blood.V110.11.307.307

Published: 2007

Journal Articles

AVE5026, a New Anticoagulant for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery - TREK: A Dose Ranging Study.

Michael R. Lassen, MD, Ola E. Dahl, MD, Patrick Mismetti, MD, Dominique Destrée, MD

Blood (2007) 110 (11): 311.

https://doi.org/10.1182/blood.V110.11.311.311

Published: 2007

Journal Articles

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Bengt I. Eriksson, MD, PhD, Ola E. Dahl, MD,PhD, Cornelis N. van Dijk, MD,PhD, Simon P. Frostick, MA,DM,FRCS, Andreas A. Kurth, MD,PhD, Nadia Rosencher, MD, Janet Schnee, MD, Rohan Hettiarachchi, MD,PhD, Anita V. Christiansen, MSc.Pharm., Stefan Hantel, PhD, Harry R. Büller, MD,PhD

Blood (2006) 108 (11): 573.

https://doi.org/10.1182/blood.V108.11.573.573

Published: 2006

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Bengt I. Eriksson, MD, PhD, Lars Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Frank Misselwitz, MD, PhD, Eva Muehlhofer, PhD, Peter Kälebo, MD, PhD

Blood (2005) 106 (11): 280.

https://doi.org/10.1182/blood.V106.11.280.280

Published: 2005

NARROW

Cluster Analysis Followed by Network Meta-Analysis to Compare Efficacy and Safety of Dabigatran, Rivaroxaban and Apixaban After Elective Total Knee and Hip Replacement Surgery

Validation of the HEMOCLOT ® Direct Thrombin Inhibitor Assay for Dabigatran by Comparison with a Validated LC-MS/MS Method in Plasma Samples From Patients After Major Orthopaedic Surgery

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Extended Thromboprophylaxis with Rivaroxaban Compared with Short-Term Thromboprophylaxis with Enoxaparin after Total Hip Arthroplasty: The RECORD2 Trial.

AVE5026, a New Anticoagulant for the Prevention of Venous Thromboembolism in Total Knee Replacement Surgery - TREK: A Dose Ranging Study.

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only